Menu Search
Equities

Twist Bioscience Corp

TWST:NSQ

Twist Bioscience Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)42.59
  • Today's Change0.93 / 2.23%
  • Shares traded295.96k
  • 1 Year change+78.87%
  • Beta1.7797
Data delayed at least 15 minutes, as of Nov 22 2024 18:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform6
Hold2
Sell1
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Twist Bioscience Corp have a median target of 53.50, with a high estimate of 62.00 and a low estimate of 47.90. The median estimate represents a 28.42% increase from the last price of 41.66.
High48.8%62.00
Med28.4%53.50
Low15.0%47.90

Earnings history & estimates in USD

On Nov 18, 2024, Twist Bioscience Corp reported 4th quarter 2024 losses of -0.590 per share. This result exceeded the -0.71 consensus loss of the 10 analysts covering the company and exceeded last year's 4th quarter results by 27.16%.
The next earnings announcement is expected on Jan 31, 2025.
Average growth rate-6.03%
Twist Bioscience Corp reported annual 2024 losses of -3.60 per share on Nov 18, 2024.
Average growth rate-1.40%
More ▼

Revenue history & estimates in USD

Twist Bioscience Corporation had 4th quarter 2024 revenues of 84.71m. This bettered the 82.20m consensus of the 10 analysts covering the company. This was 56.17% above the prior year's 4th quarter results.
Average growth rate+6.07%
Twist Bioscience Corporation had revenues for the full year 2024 of 312.97m. This was 27.69% above the prior year's results.
Average growth rate+37.20%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.